Veracyte (VCYT) Q2 Revenue Jumps 14%

Veracyte (VCYT) reported robust Q2 2025 results, with GAAP revenue of $130.2 million and non-GAAP EPS of $0.44, significantly surpassing analyst estimates. This strong performance was primarily driven by its Decipher Prostate test, which saw a 24% revenue increase, contributing to a 49% year-over-year rise in adjusted EBITDA to $35.8 million, representing a 27.5% margin. Despite a GAAP net loss of $1.0 million due to a one-time $20.5 million impairment from the wind-down of its French subsidiary, the company raised its full-year 2025 revenue guidance to $496-$504 million and adjusted EBITDA margin to 23.5%, signaling continued confidence in its core testing business and strategic expansion.

Analysis

Veracyte reported a robust second quarter for 2025, significantly outperforming analyst expectations with GAAP revenue of $130.2 million, a 7.6% beat, and non-GAAP EPS of $0.44. The primary growth engine was the Decipher Prostate test, which saw revenue climb 24% to $76.3 million on a 28% increase in volume, marking its thirteenth consecutive quarter of over 25% year-over-year volume growth. This performance underscores the test's strong market adoption, further bolstered by its recent commercial launch for metastatic patients. Profitability demonstrated significant leverage, with adjusted EBITDA growing 49% year-over-year to $35.8 million, expanding the adjusted EBITDA margin to 27.5%. Despite these operational strengths, the company reported a GAAP net loss of $1.0 million, directly attributable to a one-time $20.5 million impairment charge from the strategic wind-down of its French subsidiary. Management's confidence is reflected in raised full-year 2025 guidance, now targeting total revenue of $496-$504 million and an adjusted EBITDA margin of 23.5%, signaling sustained momentum in its core testing business.

Key Decisions for Investors

• The strong beat-and-raise quarter, driven by sustained momentum in the high-margin Decipher franchise, reinforces the bull case for the company's growth and profitability trajectory.
• Investors should look past the GAAP net loss caused by the $20.5 million non-recurring impairment charge and focus on the underlying operational health, particularly the 49% growth in adjusted EBITDA and improved cash flow.
• Closely monitor the revenue versus volume growth for the Afirma test for any signs of sustained pricing or payer mix pressure, and track execution on the forthcoming Minimal Residual Disease (MRD) platform as a key future catalyst.